<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01129518</url>
  </required_header>
  <id_info>
    <org_study_id>2008_06</org_study_id>
    <nct_id>NCT01129518</nct_id>
  </id_info>
  <brief_title>Can we Reduce the Number of Vaccine Injections for Children?</brief_title>
  <acronym>MALTA</acronym>
  <official_title>An Open Label Randomised Controlled Study to Evaluate the Induction of Immune Memory Following Infant Vaccination With a Glycoconjugate Neisseria Meningitidis Serogroup C Vaccine and to Assess the Immunological Impact of Administering Routine Infant Immunisations in Consistent Versus Alternating Limbs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oxford University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open label randomised controlled study will evaluate the induction of immunity following&#xD;
      varying schedules of vaccination with glyco-conjugate Neisseria meningitidis serogroup C&#xD;
      (MenC) vaccines in infancy. 498 infants will be enrolled in this multi-centre trial.&#xD;
      Participants will receive either 0, 1, or 2 priming doses of a MenC-CRM197 conjugate vaccine&#xD;
      or 1 priming dose of a MenC-TT conjugate vaccine in the first year of life, with all groups&#xD;
      receiving a dose of a combination Hib-MenC-TT vaccine at 12 months, as well as all other&#xD;
      concurrent routine vaccinations. All groups will also be further divided into 2 groups to&#xD;
      receive their routine vaccines in either consistent or alternating limbs to assess the immune&#xD;
      response to the concurrent infant routine immunisations administered in consistent versus&#xD;
      alternating limbs. Immune responses will be assessed at 5, 12, 12months +6 days, 13 and 24&#xD;
      months of age.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric mean titres (GMTs) of meningococcal serogroup C (MenC) specific serum bactericidal antibodies, using rabbit complement (rSBA)</measure>
    <time_frame>1 month after a 12 month dose of Hib-MenC vaccine</time_frame>
    <description>To demonstrate non-inferiority of the geometric mean titres (GMTs) of meningococcal serogroup C (MenC) specific serum bactericidal antibodies, using rabbit complement (rSBA), 1 month after a 12 month dose of Hib-MenC vaccine in children receiving a single dose of MenC-CRM197vaccine at 3 months of age (single dose priming) compared with those receiving 2 doses at 3 and 4 months of age (2 dose priming).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">404</enrollment>
  <condition>Invasive Meningococcal Disease</condition>
  <arm_group>
    <arm_group_label>Two Dose MenC Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two doses of MenC-CRM197 priming at 3 and 4 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Dose MenC-CRM197 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of MenC-CRM197 priming at 3 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Dose MenC-TT Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose MenC-TT priming at 3 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zero dose MenC priming</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine</intervention_name>
    <description>In order to ensure proper intramuscular injection of the study vaccines, a 23G (0.5mm in diameter) needle of at least 1 inch (2.54 cm) length will be used. All vaccines will be administered intramuscularly.&#xD;
Then MenC vaccine will administered either once (at 3 months) or twice (at 3 and 4 months) depending on treatment group to either the thigh, deltoid or a combination of the two.</description>
    <arm_group_label>Single Dose MenC-CRM197 Group</arm_group_label>
    <arm_group_label>Single Dose MenC-TT Group</arm_group_label>
    <arm_group_label>Two Dose MenC Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Routine schedule immunisations except monovalent MenC vaccine</intervention_name>
    <description>Routine schedule immunisations will be given according to NHS guidelines.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Single Dose MenC-CRM197 Group</arm_group_label>
    <arm_group_label>Single Dose MenC-TT Group</arm_group_label>
    <arm_group_label>Two Dose MenC Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female infants aged 6-12 weeks at the time of the first vaccination&#xD;
             and who were born between 37 and 42 weeks of gestation&#xD;
&#xD;
          -  Infants who are known to be free from medical problems as determined by a medical&#xD;
             history and clinical examination&#xD;
&#xD;
          -  Parents or guardians who are willing for their child to participate and who would be&#xD;
             expected to comply with the requirements of the protocol&#xD;
&#xD;
          -  Parents/guardians who have given informed consent for their child's participation in&#xD;
             the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of invasive meningococcal C disease&#xD;
&#xD;
          -  Previous vaccination against meningococcal serogroup C disease&#xD;
&#xD;
          -  Planned administration/administration of vaccines, since birth, other than the study&#xD;
             vaccines (with the exception of oral rotavirus vaccine, Hepatitis B vaccine and BCG).&#xD;
&#xD;
          -  Receipt of investigational vaccines/drugs, other than the vaccines used in the study,&#xD;
             within 30 days prior to receiving the first dose of the vaccines or their planned use&#xD;
             during the study period&#xD;
&#xD;
          -  Confirmed or suspected immunosuppressive or immunodeficient conditions, including&#xD;
             human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  A family history of congenital or hereditary immunodeficiency.&#xD;
&#xD;
          -  Receipt of more than 2 weeks of immunosuppressants or immune modifying drugs, (e.g.&#xD;
             prednisolone &gt;0.5mg/kg/day)&#xD;
&#xD;
          -  History of allergy to any component of the vaccines.&#xD;
&#xD;
          -  Major congenital defects or serious chronic illness.&#xD;
&#xD;
          -  History of any neurologic disorders or seizures&#xD;
&#xD;
          -  Acute disease at the time of recruitment as defined by the presence of a moderate or&#xD;
             severe illness with or without fever (with the exception of minor illnesses such as&#xD;
             diarrhoea, mild upper respiratory infection without fever). In such situations&#xD;
             enrolment should be postponed until the participant has recovered.&#xD;
&#xD;
          -  Administration of immunoglobulins and/or any blood products since birth or planned&#xD;
             administration during the study period&#xD;
&#xD;
          -  Parents who plan to move out of the geographical area where the study would be&#xD;
             conducted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>3 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oxford Vaccine Group</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>May 21, 2010</study_first_submitted>
  <study_first_submitted_qc>May 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2010</study_first_posted>
  <last_update_submitted>November 6, 2015</last_update_submitted>
  <last_update_submitted_qc>November 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>meningococcal serogroup C</keyword>
  <keyword>vaccine</keyword>
  <keyword>conjugate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

